SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is currently a focal point of intense market debate as investors weigh its massive AI backlog and aggressive cloud infrastructure spending against credit rating concerns and volatility in key partners like OpenAI. The community remains deeply divided, with many retail traders viewing the current price as a significant value opportunity while others raise alarm over debt levels and recent downward technical pressure.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is seeing significant activity following the appointment of former Disney executive Alisa Bowen as the new CEO, fueling investor optimism for a potential operational turnaround and strategic shift. While the community remains divided over the company's past leadership and recent stock performance, many are closely watching for signs of improved integration with Disney's ecosystem and potential future profitability.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Q32 Bio is seeing high volatility as traders react to positive 36-week trial results for its alopecia areata drug, bempikibart, which the community is heavily debating regarding its long-term commercial potential. While the stock has attracted significant retail momentum and volume, many participants are cautioning about potential dilution risks and profit-taking pressure following its recent sharp price appreciation.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility driven by market rotation between software and semiconductor sectors, coupled with heavy retail debate over its valuation and the launch of its new social platform, Gist. Investors are closely monitoring its technical support levels around the 450-500 range, with community sentiment sharply divided between those viewing the price swings as prime accumulation opportunities and those dismissing the stock as a highly manipulated asset.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid intense community speculation regarding the health and status of high-profile political figures, coupled with volatile reactions to the company's ongoing involvement in geopolitical tensions in the Middle East. Investors are actively debating the stock's long-term viability as discourse shifts between speculative financial theories and the political controversy surrounding current U.S. foreign policy.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is currently experiencing significant momentum and investor interest, driven by its recent expansion into Medicare coverage for multiple cancer indications and its strategic role in the cancer vaccine pipeline. The community is actively debating the stock's long-term potential, focusing heavily on its commercial partnership with Tempus and the upcoming readout of crucial clinical data that could validate the company's ultra-sensitive MRD platform.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market participants are actively debating whether SPY is experiencing a genuine price distribution or a manipulated trap as traders react to geopolitical escalation in the Strait of Hormuz and upcoming economic data releases. Sentiment remains polarized, with many community members expressing frustration over intraday chop and algorithmic volatility while others look for signs of a potential V-shaped recovery.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is surging as renewed military strikes against Iran and the collapse of the latest ceasefire agreement reignite fears of instability in the Strait of Hormuz. Investors are closely monitoring the geopolitical landscape and escalating conflict, while the community remains divided over whether the volatility represents a structural shift in energy supply or another temporary headline-driven market trap.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is experiencing high investor interest driven by strong prescription growth, a clear path to profitability in the coming quarters, and institutional accumulation that has fueled speculation regarding a potential buyout. While the stock has faced volatility and short-selling pressure, the community remains heavily bullish, citing the company's superior GI-focused product performance and recent label expansion as key catalysts for long-term value creation.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility driven by a combination of regional institutional rebalancing, anticipation surrounding the upcoming SK Hynix US IPO, and an impending 20-for-1 stock split. The community is actively debating whether these sharp pullbacks represent a structural trend reversal or a strategic buying opportunity given the high demand for memory and AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

🚨$MRK is caught in the ultimate &quot;damned if you do, damned if you don&#39;t&quot; trap. They&#39;re staring down the barrel of Keytruda&#39;s patent-losing a $30 B/year cash cow. If they sit on their hands, their oncology empire is  cooked. 
 
The unfortunate part about trying to play it safe? $LLY is sitting on crazy cash from their obesity drugs and can drop  $100B on $SLS and not even blink If Merck is forced to bid anyway, why not blow the doors off the hinges early and make the competition pay WAY MORE to match them? 
 
If I’m Merck, I don’t wait for the readout. I slide  $40B opening bid across the table right now to lock down the platform ($215+/share). If $LLY or $JNJ try to jump in, Merck needs to have the banks lined up to drop another $60B immediately. Force others to either walk away or completely over-leverage themselves just to stay in the room. 
 
A $100B bid isn&#39;t crazy they still make money over the years PLUS $SLS WT1 tech covers 20+ cancers. Buyout forces $MRK to go big or go home.

Hawk1979

Vincent Fazio

Bottsy

Gopirates1869

Sebast

Szepen

Jeff Freedman

bikechain

Dew' Moore

Nuutti

Scott

Cud Gel

BJ Carlucci

양이는귀여워

Bennyterner

Chris

Adam Roberts

Longnstrongdong

Userttt

David Walters

Sascha Bennertz

nick

Ron Jansen

Chessdoc

Appieama

Mohamad abou ardini

Stephen

StockTwits for iOS

StockTwits For Android 

StockTwits Web

Lilly(Eli) & Co

SELLAS Life Sciences Group Inc

Johnson & Johnson

Merck & Co Inc

 is caught in the ultimate "damned if you do, damned if you don't" trap. They're staring down the barrel of Keytruda's patent-losing a $30 B/year cash cow. If they sit on their hands, their oncology empire is  cooked. 
 
The unfortunate part about trying to play it safe? 

 is sitting on crazy cash from their obesity drugs and can drop  $100B on 

 and not even blink If Merck is forced to bid anyway, why not blow the doors off the hinges early and make the competition pay WAY MORE to match them? 
 
If I’m Merck, I don’t wait for the readout. I slide  $40B opening bid across the table right now to lock down the platform ($215+/share). If 

 try to jump in, Merck needs to have the banks lined up to drop another $60B immediately. Force others to either walk away or completely over-leverage themselves just to stay in the room. 
 
A $100B bid isn't crazy they still make money over the years PLUS 

 WT1 tech covers 20+ cancers. Buyout forces 

@dewmoore Excellent stuff!  This will get reposted nearer to opening bell!

 Excellent stuff!  This will get reposted nearer to opening bell!

@dewmoore I do believe $MRK has the strongest incentive to buy $SLS of any of the big pharmaceutical companies companies given the threat to the company posed by the looming expiration of the Keytruda patent

Juhana Tikkanen

Steve D

 of any of the big pharmaceutical companies companies given the threat to the company posed by the looming expiration of the Keytruda patent

10xorbust

@dewmoore It is not only the data readout that is a risk for a Merck purchase but the TAM for this indication is quite small so they would really be taking a risk that it could be expanded to other indications.  I do not think that, given those risks, that it would be something they would pay up for.

Ave Belder

 It is not only the data readout that is a risk for a Merck purchase but the TAM for this indication is quite small so they would really be taking a risk that it could be expanded to other indications.  I do not think that, given those risks, that it would be something they would pay up for.